Ekspertenes biotekfavoritter i urolige tider – E24 Ina Vedde-Fjærestad Publisert: Publisert: 5. februar 2021 Etter…
Continue Reading-
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS- 248 in patients with systemic sclerosis
Stockholm, Sweden, January 26, 2020 – Gesynta Pharma AB today announced that the first patients…
Continue Reading -
Abliva appoints Ellen Donnelly as new CEO as they enter a new development stage
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of…
Continue Reading -
Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-002 study…
Continue Reading -
Helsestartups får stryk på mangfold, e24.no Kvinner er kraftig underrepresentert både i ledelsen og i styrene til helsestartups. Ingrid Teigland Akay…
Continue Reading -
Galecto Publishes GB0139 Phase 2a (IPF) Results in European Respiratory Journal
Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing…
Continue Reading -
Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of…
Continue Reading -
Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of…
Continue Reading -
Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial
Safety review of second dose-level cohort allows study to advance to third cohort of colorectal…
Continue Reading -
Galecto Announces Pricing of Initial Public Offering
BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a…
Continue Reading